Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 412

1.

Utilization and outcomes of early respiratory support in 6.5 million acute heart failure hospitalizations.

Metkus TS, Stephens RS, Schulman S, Hsu S, Morrow DA, Eid SM.

Eur Heart J Qual Care Clin Outcomes. 2019 Jun 21. pii: qcz030. doi: 10.1093/ehjqcco/qcz030. [Epub ahead of print]

PMID:
31225598
2.

Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial.

Morrow DA, Velazquez EJ, DeVore AD, Prescott MF, Duffy CI, Gurmu Y, McCague K, Rocha R, Braunwald E.

Eur Heart J. 2019 May 15. pii: ehz240. doi: 10.1093/eurheartj/ehz240. [Epub ahead of print]

PMID:
31093657
3.

Biomarker of Collagen Turnover (C-Terminal Telopeptide) and Prognosis in Patients With Non- ST -Elevation Acute Coronary Syndromes.

Zelniker TA, Jarolim P, Scirica BM, Braunwald E, Park JG, Das S, Sabatine MS, Morrow DA.

J Am Heart Assoc. 2019 May 7;8(9):e011444. doi: 10.1161/JAHA.118.011444.

4.

Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53.

Zelniker TA, Morrow DA, Mosenzon O, Gurmu Y, Im K, Cahn A, Raz I, Steg PG, Leiter LA, Braunwald E, Bhatt DL, Scirica BM.

Clin Chem. 2019 Jun;65(6):781-790. doi: 10.1373/clinchem.2018.298489. Epub 2019 Apr 15.

PMID:
30988169
5.

Incremental costs of high intensive care utilisation in patients hospitalised with heart failure.

van Diepen S, Tran DT, Ezekowitz JA, Schnell G, Wiley BM, Morrow DA, McAlister FA, Kaul P.

Eur Heart J Acute Cardiovasc Care. 2019 Apr 12:2048872619845282. doi: 10.1177/2048872619845282. [Epub ahead of print]

PMID:
30977391
6.

The Changing Face of Cardiogenic Shock: A Challenge in Cardiac Critical Care.

Morrow DA.

J Am Coll Cardiol. 2019 Apr 16;73(14):1792-1794. doi: 10.1016/j.jacc.2019.02.022. No abstract available.

PMID:
30975296
7.

Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial.

Morrow DA, Velazquez EJ, DeVore AD, Desai AS, Duffy CI, Ambrosy AP, Gurmu Y, McCague K, Rocha R, Braunwald E.

Circulation. 2019 May 7;139(19):2285-2288. doi: 10.1161/CIRCULATIONAHA.118.039331. No abstract available.

PMID:
30955360
8.

RESPONSE: Transition to Early Career in Critical Care Cardiology: Know Who You Want to Be.

Morrow DA.

J Am Coll Cardiol. 2019 Apr 9;73(13):1730. doi: 10.1016/j.jacc.2019.03.005. No abstract available.

PMID:
30947927
9.

Role of Critical Care Medicine Training in the Cardiovascular Intensive Care Unit: Survey Responses From Dual Certified Critical Care Cardiologists.

Brusca SB, Barnett C, Barnhart BJ, Weng W, Morrow DA, Soble JS, Katz JN, Wiley BM, van Diepen S, Gomez AD, Solomon MA.

J Am Heart Assoc. 2019 Mar 19;8(6):e011721. doi: 10.1161/JAHA.118.011721.

10.

Epidemiology of Shock in Contemporary Cardiac Intensive Care Units.

Berg DD, Bohula EA, van Diepen S, Katz JN, Alviar CL, Baird-Zars VM, Barnett CF, Barsness GW, Burke JA, Cremer PC, Cruz J, Daniels LB, DeFilippis AP, Haleem A, Hollenberg SM, Horowitz JM, Keller N, Kontos MC, Lawler PR, Menon V, Metkus TS, Ng J, Orgel R, Overgaard CB, Park JG, Phreaner N, Roswell RO, Schulman SP, Jeffrey Snell R, Solomon MA, Ternus B, Tymchak W, Vikram F, Morrow DA.

Circ Cardiovasc Qual Outcomes. 2019 Mar;12(3):e005618. doi: 10.1161/CIRCOUTCOMES.119.005618.

PMID:
30879324
11.

Vorapaxar for secondary prevention in the elderly with peripheral artery disease: Insights from the TRA 2°P-TIMI 50 trial.

Patel SM, Morrow DA, Kidd SK, Goodrich EL, Scirica BM, Bonaca MP.

Vasc Med. 2019 Apr;24(2):159-161. doi: 10.1177/1358863X19826681. Epub 2019 Mar 14. No abstract available.

PMID:
30868939
12.

Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing: JACC Scientific Expert Panel.

Januzzi JL Jr, Mahler SA, Christenson RH, Rymer J, Newby LK, Body R, Morrow DA, Jaffe AS.

J Am Coll Cardiol. 2019 Mar 12;73(9):1059-1077. doi: 10.1016/j.jacc.2018.12.046. Epub 2019 Feb 21. Review.

PMID:
30798981
13.

Klotho, fibroblast growth factor-23, and the renin-angiotensin system - an analysis from the PEACE trial.

Bergmark BA, Udell JA, Morrow DA, Jarolim P, Kuder JF, Solomon SD, Pfeffer MA, Braunwald E, Sabatine MS.

Eur J Heart Fail. 2019 Apr;21(4):462-470. doi: 10.1002/ejhf.1424. Epub 2019 Feb 18.

PMID:
30773798
14.

Implementation of an Emergency Department High-Sensitivity Troponin Chest Pain Pathway in the United States.

Baugh CW, Scirica BM, Januzzi JL, Morrow DA, Lewandrowski KB, Jarolim P, White BA, Weinfeld MS, Hoffmann U, Nagurney JT.

Crit Pathw Cardiol. 2019 Mar;18(1):1-4. doi: 10.1097/HPC.0000000000000164. No abstract available.

PMID:
30747757
15.

Classification of Deaths in Cardiovascular Outcomes Trials.

Morrow DA, Wiviott SD.

Circulation. 2019 Feb 12;139(7):874-876. doi: 10.1161/CIRCULATIONAHA.118.038359. No abstract available.

PMID:
30742536
16.

Prognostic role of GDF-15 across the spectrum of clinical risk in patients with NSTE-ACS.

Zelniker TA, Jarolim P, Silverman MG, Bohula EA, Park JG, Bonaca MP, Scirica BM, Morrow DA.

Clin Chem Lab Med. 2019 Jun 26;57(7):1084-1092. doi: 10.1515/cclm-2018-1081.

PMID:
30710475
17.

Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48.

Berg DD, Ruff CT, Jarolim P, Giugliano RP, Nordio F, Lanz HJ, Mercuri MF, Antman EM, Braunwald E, Morrow DA.

Circulation. 2019 Feb 5;139(6):760-771. doi: 10.1161/CIRCULATIONAHA.118.038312.

PMID:
30586727
18.

Fourth Universal Definition of Myocardial Infarction (2018).

Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction.

Circulation. 2018 Nov 13;138(20):e618-e651. doi: 10.1161/CIR.0000000000000617. No abstract available. Erratum in: Circulation. 2018 Nov 13;138(20):e652.

PMID:
30571511
19.

Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54.

Bonaca MP, Wiviott SD, Morrow DA, Steg PG, Hamm C, Bhatt DL, Storey RF, Cohen M, Kuder J, Im K, Magnani G, Budaj A, Nicolau JC, Parkhomenko A, López-Sendón J, Dellborg M, Diaz R, Van de Werf F, Corbalán R, Goudev A, Jensen EC, Johanson P, Braunwald E, Sabatine MS.

J Am Heart Assoc. 2018 Nov 20;7(22):e009260. doi: 10.1161/JAHA.118.009260.

20.

Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function.

Correa S, Bonaca MP, Scirica BM, Murphy SA, Goodrich EL, Morrow DA, O'Donoghue ML.

J Thromb Thrombolysis. 2019 Apr;47(3):353-360. doi: 10.1007/s11239-018-1779-y.

PMID:
30511258
21.

Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial).

Vaduganathan M, White WB, Charytan DM, Morrow DA, Liu Y, Zannad F, Cannon CP, Bakris GL; EXAMINE Investigators.

Am J Cardiol. 2019 Feb 1;123(3):382-391. doi: 10.1016/j.amjcard.2018.10.035. Epub 2018 Nov 6.

PMID:
30477800
22.

Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.

Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E; PIONEER-HF Investigators.

N Engl J Med. 2019 Feb 7;380(6):539-548. doi: 10.1056/NEJMoa1812851. Epub 2018 Nov 11. Erratum in: N Engl J Med. 2019 Mar 14;380(11):1090.

PMID:
30415601
23.

Cystatin C for Risk Stratification in Patients After an Acute Coronary Syndrome.

Correa S, Morrow DA, Braunwald E, Davies RY, Goodrich EL, Murphy SA, Cannon CP, O'Donoghue ML.

J Am Heart Assoc. 2018 Oct 16;7(20):e009077. doi: 10.1161/JAHA.118.009077.

24.

[Fourth universal definition of myocardial infarction (2018)].

Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, Mickley H, Crea F, Van de Werf F, Bucciarelli-Ducci C, Katus HA, Pinto FJ, Antman EM, Hamm CW, De Caterina R, Januzzi JL Jr, Apple FS, Alonso Garcia MA, Underwood SR, Canty JM Jr, Lyon AR, Devereaux PJ, Zamorano JL, Lindahl B, Weintraub WS, Newby LK, Virmani R, Vranckx P, Cutlip D, Gibbons RJ, Smith SC, Atar D, Luepker RV, Robertson RM, Bonow RO, Steg PG, O'Gara PT, Fox KAA.

Kardiol Pol. 2018;76(10):1383-1415. doi: 10.5603/KP.2018.0203. Polish. No abstract available.

25.

Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials.

Berg DD, Wiviott SD, Braunwald E, Guo J, Im K, Kashani A, Gibson CM, Cannon CP, Morrow DA, Bhatt DL, Mega JL, O'Donoghue ML, Antman EM, Newby LK, Sabatine MS, Giugliano RP.

Eur Heart J. 2018 Nov 7;39(42):3810-3820. doi: 10.1093/eurheartj/ehy556.

PMID:
30239711
26.

Positive Pressure Ventilation in the Cardiac Intensive Care Unit.

Alviar CL, Miller PE, McAreavey D, Katz JN, Lee B, Moriyama B, Soble J, van Diepen S, Solomon MA, Morrow DA; ACC Critical Care Cardiology Working Group.

J Am Coll Cardiol. 2018 Sep 25;72(13):1532-1553. doi: 10.1016/j.jacc.2018.06.074. Review.

PMID:
30236315
27.

RESPONSE: Training in Critical Care Cardiology: Navigating a Field in Transition.

Morrow DA.

J Am Coll Cardiol. 2018 Sep 4;72(10):1174-1175. doi: 10.1016/j.jacc.2018.07.025. No abstract available.

PMID:
30165990
28.

Fourth universal definition of myocardial infarction (2018).

Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; ESC Scientific Document Group .

Eur Heart J. 2019 Jan 14;40(3):237-269. doi: 10.1093/eurheartj/ehy462. No abstract available.

PMID:
30165617
29.

Fourth Universal Definition of Myocardial Infarction (2018).

Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction.

Glob Heart. 2018 Dec;13(4):305-338. doi: 10.1016/j.gheart.2018.08.004. Epub 2018 Aug 25. Review. No abstract available.

PMID:
30154043
30.

Fourth Universal Definition of Myocardial Infarction (2018).

Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction.

J Am Coll Cardiol. 2018 Oct 30;72(18):2231-2264. doi: 10.1016/j.jacc.2018.08.1038. Epub 2018 Aug 25. No abstract available.

PMID:
30153967
31.

Progressive myocardial injury is associated with mortality in the acute respiratory distress syndrome.

Metkus TS, Guallar E, Sokoll L, Morrow DA, Tomaselli G, Brower R, Kim BS, Schulman S, Korley FK.

J Crit Care. 2018 Dec;48:26-31. doi: 10.1016/j.jcrc.2018.08.009. Epub 2018 Aug 16.

PMID:
30138905
32.

Prospective registry of cardiac critical illness in a modern tertiary care Cardiac Intensive Care Unit.

Watson RA, Bohula EA, Gilliland TC, Sanchez PA, Berg DD, Morrow DA.

Eur Heart J Acute Cardiovasc Care. 2018 Jul 1:2048872618789053. doi: 10.1177/2048872618789053. [Epub ahead of print]

PMID:
30033736
33.

Serial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial.

Jarolim P, White WB, Cannon CP, Gao Q, Morrow DA.

Diabetes Care. 2018 Jul;41(7):1510-1515. doi: 10.2337/dc18-0109. Epub 2018 May 30.

PMID:
29848776
34.

Validation of the Seattle angina questionnaire in women with ischemic heart disease.

Patel KK, Arnold SV, Chan PS, Tang Y, Jones PG, Guo J, Buchanan DM, Qintar M, Decker C, Morrow DA, Spertus JA.

Am Heart J. 2018 Jul;201:117-123. doi: 10.1016/j.ahj.2018.04.012. Epub 2018 Apr 21.

PMID:
29772387
35.

Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial.

Bergmark BA, Udell JA, Morrow DA, Cannon CP, Steen DL, Jarolim P, Budaj A, Hamm C, Guo J, Im K, Kuder JF, Braunwald E, Sabatine MS, O'Donoghue ML.

JAMA Cardiol. 2018 Jun 1;3(6):473-480. doi: 10.1001/jamacardio.2018.0653.

36.

Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial.

Velazquez EJ, Morrow DA, DeVore AD, Ambrosy AP, Duffy CI, McCague K, Hernandez AF, Rocha RA, Braunwald E.

Am Heart J. 2018 Apr;198:145-151. doi: 10.1016/j.ahj.2018.01.004. Epub 2018 Jan 10.

37.

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials.

Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Thanh Hai MT, Jaff MR, Joffe HV, Cutlip DE, Desai AS, Lewis EF, Gibson CM, Landray MJ, Lincoff AM, White CJ, Brooks SS, Rosenfield K, Domanski MJ, Lansky AJ, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L, O'Connor CM, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ; Standardized Data Collection for Cardiovascular Trials Initiative (SCTI).

J Am Coll Cardiol. 2018 Mar 6;71(9):1021-1034. doi: 10.1016/j.jacc.2017.12.048. Review.

38.

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials.

Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Hai MTT, Jaff MR, Joffe HV, Cutlip DE, Desai AS, Lewis EF, Gibson CM, Landray MJ, Lincoff AM, White CJ, Brooks SS, Rosenfield K, Domanski MJ, Lansky AJ, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L, O'Connor CM, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ; Standardized Data Collection for Cardiovascular Trials Initiative (SCTI).

Circulation. 2018 Feb 27;137(9):961-972. doi: 10.1161/CIRCULATIONAHA.117.033502. Review.

PMID:
29483172
39.

Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes.

Garlo KG, White WB, Bakris GL, Zannad F, Wilson CA, Kupfer S, Vaduganathan M, Morrow DA, Cannon CP, Charytan DM.

Clin J Am Soc Nephrol. 2018 Mar 7;13(3):398-405. doi: 10.2215/CJN.05280517. Epub 2018 Jan 16.

40.

Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease.

Bergmark BA, Bhatt DL, Braunwald E, Morrow DA, Steg PG, Gurmu Y, Cahn A, Mosenzon O, Raz I, Bohula E, Scirica BM.

Diabetes Care. 2018 Mar;41(3):577-585. doi: 10.2337/dc17-1736. Epub 2017 Dec 1.

41.

Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis.

Cavallari I, Morrow DA, Creager MA, Olin J, Bhatt DL, Steg PG, Storey RF, Cohen M, Scirica BS, Piazza G, Goodrich EL, Braunwald E, Sabatine MS, Bonaca MP.

Circulation. 2018 Feb 13;137(7):684-692. doi: 10.1161/CIRCULATIONAHA.117.031062. Epub 2017 Oct 30.

PMID:
29084737
42.

Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) Trial.

Fanola CL, Morrow DA, Cannon CP, Jarolim P, Lukas MA, Bode C, Hochman JS, Goodrich EL, Braunwald E, O'Donoghue ML.

J Am Heart Assoc. 2017 Oct 24;6(10). pii: e005637. doi: 10.1161/JAHA.117.005637.

43.

High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial.

Hwang YC, Morrow DA, Cannon CP, Liu Y, Bergenstal R, Heller S, Mehta C, Cushman W, Bakris GL, Zannad F, White WB.

Diabetes Obes Metab. 2018 Mar;20(3):654-659. doi: 10.1111/dom.13136. Epub 2017 Nov 21.

44.

De-escalation of support with veno-arterial extracorporeal membrane oxygenation and Impella for cardiogenic shock.

DeFilippis EM, Keller SP, Morrow DA.

Eur J Heart Fail. 2018 Mar;20(3):621-622. doi: 10.1002/ejhf.953. Epub 2017 Sep 26. No abstract available.

45.

Soluble interleukin-13rα1: a circulating regulator of glucose.

Rachmin I, O'Meara CC, Ricci-Blair EM, Feng Y, Christensen EM, Duffy JF, Zitting KM, Czeisler CA, Pancoast JR, Cannon CP, O'Donoghue ML, Morrow DA, Lee RT.

Am J Physiol Endocrinol Metab. 2017 Dec 1;313(6):E663-E671. doi: 10.1152/ajpendo.00168.2017. Epub 2017 Sep 5.

46.

Reply: Ezetimibe, Risk Stratification, and Secondary Prevention.

Bohula EA, Morrow DA, Giugliano RP, Cannon CP, Braunwald E.

J Am Coll Cardiol. 2017 Aug 29;70(9):1200. doi: 10.1016/j.jacc.2017.05.074. No abstract available.

47.

Trends in Cardiac Critical Care: Reshaping the Cardiac Intensive Care Unit.

Morrow DA.

Circ Cardiovasc Qual Outcomes. 2017 Aug;10(8):e004010. doi: 10.1161/CIRCOUTCOMES.117.004010. No abstract available.

PMID:
28794123
48.

Organizational Structure, Staffing, Resources, and Educational Initiatives in Cardiac Intensive Care Units in the United States: An American Heart Association Acute Cardiac Care Committee and American College of Cardiology Critical Care Cardiology Working Group Cross-Sectional Survey.

van Diepen S, Fordyce CB, Wegermann ZK, Granger CB, Stebbins A, Morrow DA, Solomon MA, Soble J, Henry TD, Gilchrist IC, Katz JN, Cohen MG, Newby LK.

Circ Cardiovasc Qual Outcomes. 2017 Aug;10(8):e003864. doi: 10.1161/CIRCOUTCOMES.117.003864. No abstract available.

49.

Acute Myocardial Infarction.

Anderson JL, Morrow DA.

N Engl J Med. 2017 May 25;376(21):2053-2064. doi: 10.1056/NEJMra1606915. Review. No abstract available.

PMID:
28538121
50.

Ranolazine in Symptomatic Diabetic Patients Without Obstructive Coronary Artery Disease: Impact on Microvascular and Diastolic Function.

Shah NR, Cheezum MK, Veeranna V, Horgan SJ, Taqueti VR, Murthy VL, Foster C, Hainer J, Daniels KM, Rivero J, Shah AM, Stone PH, Morrow DA, Steigner ML, Dorbala S, Blankstein R, Di Carli MF.

J Am Heart Assoc. 2017 May 4;6(5). pii: e005027. doi: 10.1161/JAHA.116.005027.

Supplemental Content

Loading ...
Support Center